Repligen ( (RGEN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Repligen shares are rebounding sharply after a steep six-session slide left the stock near its 52-week lows, drawing in buyers who see it as oversold and signaling a shift in sentiment. Investors are reacting to renewed confidence in the company’s long-term role in the bioprocessing market following a recent industry conference.
Supporting the rally, RBC Capital recently reiterated an Outperform rating and set a $160 price target, while another analyst report flagged as much as 73% potential upside. The combination of technical recovery and bullish analyst coverage is fueling speculation that Repligen’s downturn may have run its course and that a new uptrend could be starting.
More about Repligen
YTD Price Performance: -36.41%
Average Trading Volume: 1,067,760
Technical Sentiment Signal: Sell
Current Market Cap: $5.8B
For further insights into RGEN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.